Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)

被引：0
|
作者：
Sun, M. [1 ]
Spigel, D. R. [2 ]
Lee, Y-J. [3 ]
Yoon, H. [4 ]
Liu, Y. [5 ,6 ]
Ahern, E. [7 ]
Harris, S. [8 ]
Lee, G-W. [9 ,10 ]
Yan, D. [11 ]
Chen, J. [12 ]
Shiah, H-S. [13 ]
Deng, T. [14 ]
Zheng, H. [15 ]
Tan, W. [16 ]
Zhou, Z. [16 ]
Wang, R. [16 ]
Ba, Y. [14 ]
机构：
[1] Shandong First Med Univ, Dept Oncol, Cent Hosp, Jinan, Peoples R China
[2] Sarah Cannon Res Inst, Dept Med Oncol, Nashville, TN USA
[3] Natl Canc Ctr Hosp, Dept Internal Med, Goyang, South Korea
[4] Mayo Clin, Dept Oncol, Rochester, MN USA
[5] Zhengzhou Univ, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
[7] Monash Hlth, Med Oncol, Clayton, Vic, Australia
[8] Bendigo Hlth, Dept Med Oncol, Bendigo, Vic, Australia
[9] Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea
[10] Gyeongsang Natl Univ, Coll Med, Jinju, South Korea
[11] Capital Med Univ, Beijing Luhe Hosp, Dept Oncol, Beijing, Peoples R China
[12] Cent South Univ, Dept Thorac Med Oncol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China
[13] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Div Hematol & Oncol, Dept Med, New Taipei, Taiwan
[14] Natl Clin Res Ctr Canc, Dept GI Med Oncol, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[15] BeiGene USA Inc, San Mateo, CA USA
[16] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1445
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1533P
引用
收藏
页码：S862 / S863
页数：2
相关论文
共 32 条
  • [1] AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
    Kim, Se Hyun
    Lee, Gyeong-Won
    Shim, Byoung Yong
    Spigel, David R.
    Shiah, Her-Shyong
    Frentzas, Sophia
    Yoon, Harry H.
    Wang, Feng
    Sun, Meili
    Clay, Timothy Dudley
    Zheng, Hao
    Tan, Wei
    Zhou, Ziqi
    Wang, Ruihua
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
    Yu, Y.
    Huang, D.
    Gao, B.
    Zhao, J.
    Hu, Y.
    Zhuang, W.
    Kao, S.
    Xu, W.
    Yao, Y.
    Yang, T-Y.
    Lee, Y.
    Kim, J-S.
    Shiah, H-S.
    Wang, R.
    Zheng, H.
    Tan, W.
    Gao, R.
    Kim, H. R.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1019 - S1019
  • [3] AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
    Kumar, R.
    Kim, S. H.
    Zhong, D.
    Lu, S.
    Cheng, Y.
    Chen, M.
    Cho, E.
    Clay, T.
    Kang, J. -H.
    Lee, G. -W.
    Sun, M.
    Shim, B. -Y.
    Spigel, D. R.
    Yang, T. -Y.
    Wang, Q.
    Chang, G. -C.
    Yu, G.
    Wang, R.
    Luo, X.
    Zheng, H.
    Gao, R.
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S375 - S376
  • [4] PERIPHERAL PHARMACODYNAMIC (PD) EFFECTS OF OCIPERLIMAB (OCI) IN COMBINATION WITH TISLELIZUMAB (TIS) IN PATIENTS WITH ADVANCED SOLID TUMORS: ADVANTIG-105 PHASE 1 DOSEESCALATION STUDY
    Tan, Wei
    Shi, Yang
    Yan, Han
    Shen, Zhirong
    Budha, Nageshwar
    Rizwan, Ahsan
    Huang, Ruiqi
    Zheng, Hao
    Gao, Rang
    Frentzas, Sophia
    Kao, Steven
    Meniawy, Tarek
    Zhang, Yun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A799 - A799
  • [5] AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
    Wang, F.
    Lin, C-Y.
    Sun, J-M.
    Lu, C-H.
    Zhu, X.
    Chen, Z.
    Kim, I-H.
    Pan, Y.
    Zhang, J.
    Chen, Z.
    Tougeron, D.
    Kim, S-B.
    Van Cutsem, E.
    Abdrashitov, R.
    Ge, R.
    Sun, J.
    Zhou, J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S621 - S621
  • [6] Cost-effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
    Zhang, Li
    Su, Henghai
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [7] AdvanTIG-205: Phase II trial of ociperlimab (OCI) plus tislelizumab (TIS) plus chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
    Zhu, B.
    Kim, T. M.
    Patel, S. A.
    Parakh, S.
    Tang, J.
    Wu, H.
    Girard, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1094 - S1094
  • [8] AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) plus tislelizumab (TIS)+BAT1706 (bevacizumab biosimilar) versus TIS+BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ren, Z.
    Huang, Y.
    Guo, Y.
    Hou, M. M.
    Wang, W.
    Kuang, M.
    Hao, C.
    Wang, W.
    Zhang, Y.
    Song, T.
    Dai, C.
    Hsing-Tao, K.
    Li, V.
    Abdrashitov, R.
    Wang, L.
    Fan, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S594 - S594
  • [9] AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
    Lee, J-Y.
    Wu, L.
    Boonyapipat, S.
    Kim, H. S.
    Lee, J-W.
    Wang, L.
    Wang, T.
    Wang, D.
    Yao, D.
    Liu, H.
    Andabekov, T.
    Zhang, X.
    Wang, W.
    Kim, Y. M.
    Wang, K.
    Gao, Y.
    Mu, X.
    Sinielnikov, I. Volodymyrovych
    ANNALS OF ONCOLOGY, 2023, 34 : S509 - S510
  • [10] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
    Raymond, E.
    Xu, J.
    Kato, K.
    Hubner, R.
    Shu, Y.
    Park, S. R.
    Kojima, T.
    Wyrwicz, L. S.
    Tougeron, D.
    Geboes, K.
    Van Cutsem, E.
    Pazo Cid, R. A.
    Zaanan, A.
    McLachlan, S-A.
    Wu, H.
    Shi, J.
    Li, L.
    Yan, S.
    Yoon, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S159 - S159
1234